Case-control meta-analysis of blood DNA methylation and autism spectrum disorder.
Shan V AndrewsBrooke SheppardGayle C WindhamLaura A SchieveDiana E SchendelLisa A CroenPankaj ChopraReid S AlischCraig J NewschafferStephen T WarrenAndrew P FeinbergM Daniele FallinChristine Ladd-AcostaPublished in: Molecular autism (2018)
No single CpG site showed a large enough DNAm difference between cases and controls to achieve epigenome-wide significance in this sample size. However, our results suggest the potential to observe disease associations from blood-based samples. Among the seven sites achieving suggestive statistical significance, we observed consistent, and stronger, effects at the same sites among brain samples. Discovery-oriented EWAS for ASD using blood samples will likely need even larger samples and unified genetic data to further understand DNAm differences in ASD.
Keyphrases
- autism spectrum disorder
- dna methylation
- case control
- systematic review
- attention deficit hyperactivity disorder
- genome wide
- intellectual disability
- gene expression
- small molecule
- randomized controlled trial
- electronic health record
- copy number
- multiple sclerosis
- risk assessment
- big data
- subarachnoid hemorrhage
- functional connectivity